KISQALI® (ribociclib) prescribing information (external link)
TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) prescribing information (external link)
SANDOSTATIN® LAR® (octreotide acetate) prescribing information (external link)
This page includes promotional content created and funded by Novartis Pharmaceuticals UK Ltd. Novartis products may be mentioned.
Oncology
KISQALI® (ribociclib)
aBC resources
Video
13 mins 49 secs
Prof. Peter Fasching patient case study
Video
6 mins 36 secs
Dr Alastair Thomson patient case study
Video
7 mins 6 secs
Bleddyn Edwards patient case study
eBC resources
Video
8 mins 46 secs
Prof. Stephen Johnston risk of recurrence in HR+/HER2– eBC
TAFINLAR® (dabrafenib) + MEKINIST® (trametinib)
SANDOSTATIN® LAR® (octreotide acetate)
Video
7 mins 20 secs
How to administer and prepare SANDOSTATIN LAR
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
